Valeant Pharmaceuticals International

Valeant Pharmaceuticals International is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products. The Company's primary focus is in the areas of dermatology and eye health. In addition, the Company provides branded generic products in antibiotics, antifungal medications, diabetic therapies, antibacterials and vitamin deficiency.

Type
Public
HQ
Aliso Viejo, US
Founded
1960
Size (employees)
21,500 (est)
Valeant Pharmaceuticals International was founded in 1960 and is headquartered in Aliso Viejo, US
Report incorrect company information

Key People/Management at Valeant Pharmaceuticals International

Joe Papa

Joe Papa

CEO

Valeant Pharmaceuticals International Office Locations

Valeant Pharmaceuticals International has an office in Aliso Viejo
Show all (1)
Report incorrect company information

Valeant Pharmaceuticals International Financials and Metrics

Valeant Pharmaceuticals International Financials

Valeant Pharmaceuticals International's revenue was reported to be $8.72 b in FY, 2017
USD

Revenue (FY, 2017)

8.7 b

Gross profit (FY, 2017)

6.2 b

Gross profit margin (FY, 2017), %

71.3%

Net income (FY, 2017)

2.4 b

EBIT (FY, 2017)

102 m

Market capitalization (18-Apr-2018)

7.8 b

Cash (31-Dec-2017)

720 m
Valeant Pharmaceuticals International's current market capitalization is $7.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.8 b8.3 b10.4 b9.7 b8.7 b

Revenue growth, %

43%26%(7%)

Cost of goods sold

1.8 b2.5 b

Gross profit

3.9 b6.2 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

1.5 b1.9 b2.8 b2.1 b2.2 b

Cost of goods sold

560.9 m504.1 m634.6 m584 m635 m

Gross profit

980.9 m1.4 b2.2 b1.5 b1.6 b

Gross profit Margin, %

64%73%77%72%72%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

600.3 m322.6 m597.3 m542 m720 m

Accounts Receivable

1.8 b2.1 b2.7 b2.5 b2.1 b

Inventories

205 m641.9 m966.4 m1.1 b1 b

Current Assets

3.9 b4.2 b5.5 b5.1 b4.7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

596.3 m576.3 m531.2 m808.8 m1.9 b958 m1.4 b1.3 b852.4 m658.5 m1.2 b1.2 b

Accounts Receivable

1.6 b1.7 b1.8 b1.9 b2.1 b2.4 b2.7 b2.7 b2.7 b2.7 b2.1 b2.1 b

Inventories

1.1 b953.4 m942.5 m932.7 m998.9 m1.2 b1.2 b1.3 b1.3 b1.3 b1.1 b1.1 b

Current Assets

3.8 b4 b5.2 b4.4 b16.2 b6.3 b7 b6.2 b5.8 b5.7 b5.3 b6 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(863.7 m)912.2 m(287.8 m)(2.4 b)2.4 b

Inventories

(120 m)(170 m)(280 m)(164 m)7 m

Accounts Payable

Cash From Operating Activities

1 b2.3 b2.2 b2.1 b2.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(972 m)(20.3 m)122 m276.4 m74.5 m(51.6 m)51.7 m(372.9 m)(676.9 m)(1.9 b)629 m592 m

Depreciation and Amortization

635 m

Inventories

(46.2 m)(69.2 m)(12.1 m)(41.5 m)(38.5 m)(48.3 m)(45.6 m)(85.9 m)(145.1 m)(166.3 m)(38 m)

Cash From Operating Activities

201.7 m484.3 m376 m618.7 m491.1 m410.5 m736.5 m558.1 m1 b1.6 b954 m1.2 b
USDY, 2017

Revenue/Employee

405.8 k

Financial Leverage

6.3 x
Show all financial metrics
Report incorrect company information